INSIGHTS ON DRUG DEVELOPMENT
-
![pulmonary-GettyImages-2148494976]( "Spray Dried Biologics For Pulmonary Dosage Forms")
Spray Dried Biologics For Pulmonary Dosage FormsSpray drying creates stable inhalable biologic powders with controlled particle size, enabling effective lung delivery, improved stability, and scalable production for respiratory and systemic therapies.
-
![getty-1311598658-data-analytics]( "Enabling Quality By Design")
Enabling Quality By DesignOutdated quality systems delay product release. Discover how manufacturers can harness real-time data, operationalize QbD, and enhance compliance, efficiency, and supply chain continuity.
-
![GettyImages-2183237842-glp-1-peptide-red-light-blue-code]( "Characterizing Quality Attributes Of GLP-1 Analogs By Light Scattering")
Characterizing Quality Attributes Of GLP-1 Analogs By Light ScatteringExplore how light scattering reveals the structural integrity, aggregation, and stability of GLP-1 analogs to advance drug formulation and enhance treatment efficacy for type 2 diabetes and obesity.
-
![GettyImages-1253545551-OSD-pill-tablet-oral-solid-dose]( "How L-Leucine Shapes Spray-Dried Particles")
How L-Leucine Shapes Spray-Dried ParticlesOptimizing L-Leucine balances porosity and surface enrichment in spray-dried formulations. Precise adjustments alter particle structure to enhance aerodynamic performance and lung deposition.
-
AI Based Screening And Selection Of Co-Formers For Co-Crystallization11/4/2025
Explore how AI and quantum chemistry are accelerating co-crystal screening and solving solubility challenges in drug development, as well as key technical considerations for identifying optimal co-formers.
-
Improving Clinical Translation For ADCs And Immuno-Oncology With Human-Relevant Tumor Models9/17/2026
When preclinical tumor models fail to reflect clinical reality, promising therapies pay the price. This webinar examines how advanced patient-derived organoids and 3D models improve predictive accuracy for ADC and immuno-oncology programs.
-
Bioprocess Optimization: Leveraging Functional DOE With Time-Based Insights3/5/2025
Explore the key differences between traditional DOE and Functional DOE as Seongjin Kim demonstrates how the latter enhances bioprocess optimization through a fed-batch cell culture example.
-
Walk-Away Monitoring Of Cytotoxicity, Viability, And Apoptosis10/29/2025
Real-time cell health monitoring reveals how drug dose and timing impact apoptosis, necrosis, and viability. Explore how automated workflows help pinpoint mechanistic toxicity windows.
-
What Will It Take To Make MCED And MRD A Reality?6/30/2026
Cancer mortality is declining, but the need for earlier action remains. Gain insight into how MCED and MRD are advancing cancer detection and surveillance, helping clinicians identify disease sooner.
DRUG DEVELOPMENT SOLUTIONS
-
![Upperton-Formulation Development]( "Formulation Development")
Upperton offers formulation development services to accelerate First-in-Human studies and advance projects toward clinical trials.
-
![Supel™ BioSPME]( "Supel™ BioSPME 96-Pin Devices")
Explore a range of devices for free fraction analyses and determination of plasma protein binding that make sample preparation easier and faster, with complete phospholipid removal and proven reproducibility.
-
Decades of experience in production technologies, quality control and knowledge of the regulatory environment result in high-quality drug delivery devices that are fully optimized to perform as a system.
-
![BD-vystra]( "Disposable Pen For The Self-Injection Of Chronic Disease Medications")
This device is designed for use with a wide range of drug therapies that require variable dosing.
-
![GettyImages-899692870-lab-cleanroom-research-microscope]( "Peptide Development Strategies")
Peptides occupy a therapeutic niche between small molecules and large biologics. We understand the fundamental physiological challenges to peptide delivery and that there is no “one-size-fits-all” approach for formulation design.
